Synovial fibroblast (FLS)

Synovial fibroblasts, also known as fibroblast-like synoviocytes (FLS), are specialized mesenchymal cells that form the synovial lining of joints (Nature Reviews Rheumatology, 2018). Under physiological conditions, they maintain joint integrity by secreting lubricating factors like hyaluronic acid and organizing the extracellular matrix. In the context of rheumatoid arthritis (RA), these cells undergo a fundamental shift toward an aggressive, tumor-like phenotype, characterized by increased migration, invasion into cartilage, and resistance to programmed cell death (Arthritis & Rheumatology, 2021). They are primary producers of pro-inflammatory cytokines (such as IL-6) and matrix-degrading enzymes (such as MMPs) that drive joint destruction (Science Translational Medicine, 2019). Although synovial fibroblasts are a cell type rather than a single molecule, they are considered a critical therapeutic target population; current and emerging therapies aim to modulate their activation via JAK inhibitors or target specific surface markers like fibroblast activation protein (FAP) to halt disease progression (Annals of the Rheumatic Diseases, 2020).

Other names

Fibroblast-like synoviocyteFLSType B synoviocyteSynoviocyte

Modulation of intracellular signaling (e.g., JAK/STAT inhibition), neutralization of activating cytokines (e.g., TNF, IL-6), or potential direct targeting of fibroblast-specific surface proteins to reduce pathological activation and joint invasion.